Table 1 Patients’ demographic characteristics, drug regimen and adherence to the protocol
Patient | I | II | III | IV | V | VI | VII | VIII | IX | X | XI |
|---|---|---|---|---|---|---|---|---|---|---|---|
Sex | F | M | F | F | F | F | F | F | F | F | F |
Age (years) | 10 | 10 | 11 | 11 | 12 | 12 | 14 | 16 | 17 | 19 | 18 |
BMI (kg/m2) | 15.5 | 20.8 | 15.4 | 27.8 | 20.1 | 20.6 | 21.6 | 21.2 | 38.6 | 21.8 | 16.2 |
BMI percentile | 25th | 97th | 15th | 99th | 85th | 85th | 75th | 50th | 99th | 50th | 3th |
Duration of disease (years) | 7 | 7 | 4 | 2 | 5 | 7 | 10 | 2 | 13 | 17 | 10 |
Prednisone dose (mg/kg/day) | – | – | – | 0.16 | 0.11 | – | – | 0.51 | – | – | – |
Current use of other rheumatic drugs | HCQ, MTX | – | HCQ | HCQ, MTX | MTX | – | – | HCQ, MTX | – | – | HCQ |
CMAS (0–52 | 52 | 52 | 52 | 52 | NA | 52 | NA | 52 | 52 | NA | 50 |
MMT (0–80) | 80 | 80 | 80 | 80 | NA | 80 | NA | 80 | 80 | NA | 80 |
DAS (0–28) | 0 | 0 | 4 | 0 | NA | 4 | NA | 0 | 3 | NA | 0 |
Adherence (%) | 96.7 | 93.3 | 66.7 | 10.0 | 80.0 | 73.3 | 100 | 16.7 | 66.7 | 73.3 | 83.3 |